ClinicalTrials.gg
Sign In
BiosimilarDrug

BI 695502 clinical trials

Also written BI 695502.

A product of Bevacizumab; its studies count on that page too.

studies test it
3
open now
0
in phase 3
2
first study started
2012

How each study uses BI 695502 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
26 Feb 2004 · AVASTIN · BLA 125085 (FDA, Drugs@FDA; as Bevacizumab)
European Union
12 Jan 2005 · Avastin · EMEA/H/C/000582 (EMA; as Bevacizumab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

BI 695502
3

Studies by the year they started

3 studies that test it; most in 2012 (1)

Studies that test BI 695502, by start year
YearStudies
20121
20151
20161

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
1
Colorectal Neoplasms
1

Who runs them

Industry 3 · Other 0

Boehringer Ingelheim (3)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses BI 695502 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3